The status of hormone receptor (HR) has predictive value for endocrine therapy of breast cancer,21 while HER2 status not only can predict the outcome of systemic chemotherapy but is also a key factor in HER2‐targeted therapy.22 This evidence concerns the gene NR4A1 and breast carcinoma.